UIC Law Review
Volume 46

Issue 2

Article 5

2013

No Duty to Warn of Drug Interactions: A Dangerous Prescription,
46 J. Marshall L. Rev. 533 (2013)
Ryanne Bush Dent

Follow this and additional works at: https://repository.law.uic.edu/lawreview
Part of the Food and Drug Law Commons, Health Law and Policy Commons, Medical Jurisprudence
Commons, and the Torts Commons

Recommended Citation
Ryanne Bush Dent, No Duty to Warn of Drug Interactions: A Dangerous Prescription, 46 J. Marshall L. Rev.
533 (2013)

https://repository.law.uic.edu/lawreview/vol46/iss2/5
This Comments is brought to you for free and open access by UIC Law Open Access Repository. It has been
accepted for inclusion in UIC Law Review by an authorized administrator of UIC Law Open Access Repository. For
more information, please contact repository@jmls.edu.

Do Not Delete

3/12/2013 7:11 PM

NO DUTY TO WARN OF DRUG
INTERACTIONS: A DANGEROUS
PRESCRIPTION
RYANNE BUSH DENT*
I.

INTRODUCTION

The drug industry is a major force in the United States that
affects about half of the country’s population in any given month.1
According to the Centers for Disease Control (CDC) Office Visit
Study, in 2008, there were more than 2.3 billion “drug mentions”
at office visits in the United States in which there was medical
documentation in a patient’s record of a drug provided, prescribed,
or continued.2 Also, more than 711 million visits in the United
States in 2008 were “drug visits,” meaning drugs were either
provided or prescribed.3 In a 2011 CDC study, it stated that
prescription drug sales by retail outlets exceeded $234 billion.4

*The author would like to thank Professor Alberto Bernabe for guidance
throughout law school, including direction to the topic of this Comment.
1. Nat’l Ctr. For Health Statistics, Health, United States, 2010: With
Special Feature on Death and Dying, CTRS. FOR DISEASE CONTROL AND
PREVENTION 318 (2011), http://www.cdc.gov/nchs/data/hus/hus10.pdf#094
[hereinafter Special Feature on Death and Dying]. This part of the study asked
people whether they were taking a prescription drug currently (that month).
Id. Almost half of the participants (47.9%) were taking a prescription drug
that month. Id. Additionally, the study shows that 21.4% of the participants
indicated they were taking three or more prescription drugs that month. Id.
2. Ambulatory and Hospital Care Statistics Branch, Nat’l Ctr. For Health
Statistics, Nat’l Ambulatory Medical Care Survey: 2008 Summary Tables,
FOR
DISEASE
CONTROL
AND
PREVENTION
25
(2008),
CTRS.
http://www.cdc.gov/nchs/data/ahcd/namcs
_summary/2008_namcs_web_tables.pdf. This study showed that 2,325,368,000
documentations were made in patients’ records about drugs at an office visit.
Id. This figure, however, was capped at eight drug documentations for each
visit. Id. Therefore, if a patient was actually taking ten drugs at the time of
the office visit, only eight were counted toward this total. Id.
3. Id. In the study, a drug visit is one in which at least one drug is either
prescribed or provided. Id. Table 23 breaks each drug visit into different
physician specialties, with the total being 711,368,000. Id. This means that
74.4% of office visits were “drug visits” in which one or more drugs were
prescribed or provided. Id. Intuitively this makes sense, as most people do not
go to the doctor unless they are sick in some way, hoping that the doctor will
prescribe them medication so they can get better.
4. Special Feature on Death and Dying, supra note 1, at 369. The study
tracks national health trends in order to present the findings to the
533
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While physicians actually prescribe these drugs, pharmacists
must fill those prescriptions and make direct contact with
patients. Because prescription drugs are so vital, and yet so
dangerous, pharmacists carry a heavy burden. With this heavy
burden, there is specific education and training that pharmacists
must complete to be licensed.5
When pharmacists become licensed to practice, they agree to
abide by the established ethics of their profession.6 Many
pharmacists agree to these ethics even earlier, such as while they
are still in pharmacy school.7 Of particular importance, almost all
of the ethics guidelines relate to the patient in some capacity.8
From the onset of his pharmaceutical practice, the pharmacist
knows he owes certain duties to his patients simply by being a

President.and Congress. Id. This part of the study showed the national
expenditure for different types of medical expenses in 2008 compared to
previous years. Id.
5. U.S. Dept. of Labor, Occupational Outlook Handbook: Pharmacists
(2012-13 ed.), BUREAU OF LABOR STATISTICS (Mar. 29, 2012),
http://www.bls.gov/ooh/Healthcare/Pharmacists.htm [hereinafter BUREAU OF
LABOR STATISTICS]. To become a licensed pharmacist, students must obtain a
doctor of pharmacy (Pharm.D.) and subsequently take various licensing tests
depending on the state in which the pharmacist will practice. Id. Every state
requires that students must take the North American Licensure
ExaminationTM as well. Am. Pharm. Ass’n, Getting Your License,
PHARMACIST.COM,
https://portal.pharmacist.com/AM/Template.cfm?Section=Career_Resources&T
emplate=/CM/ContentDisplay.cfm&ContentID=11570 (last visited Jan. 19,
2013).
6. Am. Pharm. Ass’n, Code of Ethics for Pharmacists (adopted Oct. 27,
1994), PHARMACIST.COM, http://www.pharmacist.com/code-ethics (last visited
Jan. 19, 2013) [hereinafter Code of Ethics]. The American Pharmacist
Association (APhA) also has a Pharmacist Oath. Am. Pharm. Ass’n, Oath of a
Pharmacist
(adopted
July
2007),
PHARMACIST.COM,
http://www.pharmacist.com/oath-pharmacist (last visited Jan. 19, 2013)
[hereinafter Oath of a Pharmacist]. Prior to 2003, the American Pharmacists
Association was known as the American Pharmaceutical Association, and from
1994 until 2003 when it changed its name, the Association had a Code of
Ethics for Pharmacists that its members were required to uphold, which was
basically a shorter version of the Oath of a Pharmacist. See Am.
Pharmaceutical Ass’n, Code of Ethics for Pharmacists, PHARMWATCH (July 19,
2011),
http://www.pharmwatch.org/reports/ethics.shtml
(providing
the
American Pharmaceutical Association’s Code of Ethics as adopted on October
27, 1994).
7. See Am. Pharmaceutical Ass’n Acad. of Students of Pharmacy—Am.
Ass’n of Colls. of Pharmacy Council of Deans Task Force on Professionalism,
White Paper on Pharmacy Student Professionalism, 40 J. AM.
PHARMACEUTICAL ASS’N 96, 97 (2000), http://www.cop.ufl.edu/wpcontent/uploads/dept/studaff/forms/whitepaper.pdf
[hereinafter
AphAASP/AACP COD] (stating that the professionalism courses must start early in
a pharmacist’s educational career).
8. See id. at 101-02 (replicating the oaths and ethical guidelines that
pharmacists follow from different organizations).
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pharmacist.
Typically, the pharmacist does not have a general duty to
warn patients, particularly of drug interactions.9 The possibility of
liability for pharmacists is very narrow.10 The pharmacist is
usually liable only if he fills the prescription incorrectly.11 This is
mainly because the learned intermediary doctrine shields
pharmacists from liability related to the duty to warn of dangers
related to prescription drugs.12 The learned intermediary doctrine
places the responsibility on the physician, instead of the
pharmacist, to warn the patient.13
Although the legal landscape has been changing to hold
pharmacists liable in a broader context, it has not gone far
enough.14 The law currently provides for exceptions to create
pharmacist liability under circumstances when pharmacists act
negligently.15 With the technology and roles of pharmacists
changing,16 even additional exceptions later developed will not be
enough.
Instead of creating exceptions to the general rule, the old rule
should be abolished. There should be an affirmative duty on

9. See Brian L. Porto, Annotation, Civil Liability of Pharmacists or
Druggists for Failure to Warn of Potential Drug Interactions in Use of
Prescription Drug, 79 A.L.R. 5TH 409 (2000) (noting that most courts
reviewing that question have held there is no duty for pharmacists); see also
Edward Casmere, Rx for Liability: Advocating the Elimination of the
Pharmacist’s No Duty to Warn Rule, 33 J. MARSHALL L. REV. 425, 428-59
(2000) (pointing out the deficiencies of the no duty rule and advocating for the
elimination of such a rule).
10. See Morgan v. Wal-Mart Stores, Inc., 30 S.W.3d 455, 461 (Tex. App.
2000) (citing multiple Texas cases where courts found that pharmacists had no
duty to inform patients about side effects or hazards).
11. Id.
12. Leesley v. West, 518 N.E.2d 758, 763 (Ill. App. 1988).
13. Id.
14. See Porto, supra note 9, at § 2(a) (explaining that traditionally, as long
as the pharmacist accurately filled the prescription as the doctor wrote it, he
was immune from liability). See infra note 31 and accompanying text
(explaining that liability from drug interactions has historically fallen on the
prescribing physician in accordance with the learned intermediary doctrine).
15. See infra notes 46-49 and accompanying text (detailing cases with
exceptions based on assumption of risk, special knowledge, ethical duties, and
OBRA legislation).
16. Gary G. Cacciatore, Computers, OBRA 90 and the Pharmacist’s Duty to
Warn, 5 J. PHARMACY & L. 103, 116 (1996). The pharmacy industry has
become highly computerized allowing pharmacists to accurately and
effectively inquire as to drug interactions, which may eventually give rise to
even more responsibilities, not just to warn of drug interactions, but also to
check for such interactions, and to ensure that the computer system is
working properly. Id.; see also Baker v. Arbor Drugs, Inc., 544 N.W.2d 727,
731 (Mich. App. 1996) (explaining that a pharmacy may assume the duty to
warn because it advertised a computerized system to check for drug
interactions); infra note 48 and accompanying text (same).
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pharmacists to warn patients of drug interactions. The courts
should also explicitly recognize that the learned intermediary
doctrine no longer shields pharmacists who act negligently with
respect to warnings of drug interactions.
This Comment discusses the pharmacist’s duty to warn of
potential interactions between drugs, emphasizes the need to place
an affirmative duty to warn of drug interactions on pharmacists,
and argues that pharmacists should no longer be shielded by the
learned intermediary doctrine. Part II of this Comment discusses
the background of professional negligence law and how it
specifically relates to pharmacists. It also discusses how the
learned intermediary doctrine applies to pharmacists, and the
changing role of pharmacists.
Part III analyzes the current state of the law regarding
pharmacists and the no duty to warn of drug interactions rule,
with special emphasis on the learned intermediary doctrine. Part
IV proposes courts should impose an affirmative duty to warn of
drug interactions on pharmacists, created through custom or
through pharmacists’ professional standards, regardless of the
learned intermediary doctrine.
II. BACKGROUND
A. Creating a Professional Standard of Care
A professional must “exercise ordinary care in delivery of
professional services.”17 Exercising ordinary care means that the
professional is not engaging in conduct that would create an
unreasonable risk of harm.18 When this standard of care is not
met, there is a breach of the professional duty.19 When a
17. Jennings v. Badgett, 230 P.3d 861, 865 (Okla. 2010); see also
RESTATEMENT (SECOND) OF TORTS § 299A (1965) (stating the well-accepted
definition of professional liability). A professional is “required to exercise the
skill and knowledge normally possessed by members of that profession or
trade in good standing in similar communities.” Id. The Restatement also
mentions that a pharmacist is a type of profession or trade that is bound by
the same professional liability standards as other professions. Id. at cmt. b.
The standard of care thus determines what is the duty of the professional.
18. RESTATEMENT (SECOND) OF TORTS § 281 cmt. e (1965).
19. Paul M. Coltoff et al., Negligence, 65 C.J.S. Negligence § 163 (2011); see
also META B. LINDLEY, ELEMENTS OF A NEGLIGENCE CLAIM, 6 MS PRAC.
ENCYCLOPEDIA MS LAW § 52:2, MSPRAC-ENC § 52:2; RICHARD S. ROSEN ET
AL., BURDEN OF PROOF, 18 S.C. JUR. NEGLIGENCE § 13 (discussing elements of
negligence, in general); John C. P. Goldberg & Benjamin C. Zipursky, The
Restatement (Third) and the Place of Duty in Negligence Law, 54 VAND. L.
REV. 657, 684 (2001) (discussing negligence, in general, and that there can be
no breach absent a duty); BREACH OF DUTY, 9 TEX. JUR. PL & PR. FORMS
§ 178:7 (2d ed.) (defining breach of duty, generally); J.D. LEE & BARRY
LINDAHL, ELEMENTS OF NEGLIGENCE, 1 MODERN TORT LAW: LIABILITY AND
LITIGATION § 3:2 (2d ed.) (generally defining elements of negligence); LAURA
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professional breaches a duty, he may be civilly liable for damages
to the party injured in the form of a negligence action.20
The cause of action available to a plaintiff when the
professional breaches a duty is normally referred to as
malpractice.21 There are many different types of malpractice, for
example, legal or medical malpractice. For a plaintiff to prove
malpractice, he must establish negligence by proving a duty,
breach of duty, causation, and injury.22
The professional duty is typically established through the
particular profession’s custom practices.23 Custom is the

HUNTER DIETZ ET AL., EXISTENCE OR BREACH OF DUTY; LACK OF PROPER
CARE, 57B AM. JUR. 2D Negligence § 1262 (2012) (discussing the doctrine of res
ipsa loquitor).
20. See Laura Smalley, Pharmacist Malpractice: Trial and Litigation
Strategy, 78 AM. JUR. Trials 407, § 3 (2001) (explaining a patient injured by a
drug dispensed by a pharmacist may maintain tort actions against the
pharmacist, including theories based on negligence and/or failure to warn). A
malpractice action sounds in tort, and is a negligence action, thus requiring
the elements of a normal negligence action. Id. See supra notes 17 and 18
(explaining that for malpractice, however, there is a special emphasis on a
different standard of care, that of the professional).
21. VICTOR E. SCHWARTZ, KATHRYN KELLY & DAVID F. PARTLETT,
PROSSER, WADE & SCHWARTZ’S TORTS CASES AND MATERIALS 177 (12th ed.
2010).
22. See David G. Owen, The Five Elements of Negligence, 35 HOFSTRA L.
REV. 1671, 1673-74 (2007) (arguing that there are in fact five elements instead
of the traditional four which combined proximate cause and cause in fact into
one element simply called causation). A plaintiff must be able to show that a
duty was owed by the defendant to the plaintiff and what that duty was. Id. at
1674-75. The plaintiff also has the burden to prove that the defendant did not
meet that duty, showing a breach of that duty. Id. at 1676-66. If the first two
elements can be shown, the plaintiff must also show that the injury was
caused by the breach. Id. at 1679-80. Causation includes both cause in fact
and proximate cause. Id. at 1674. Finally, the plaintiff must show that the
defendant’s conduct actually caused an injury to him. Id.
23. See Advincula v. United Blood Servs., 678 N.E.2d 1009, 1027 (Ill. 1996)
(stating that generally, and in this case, the standard of care is determined by
custom in the specific professional field); see also JOHN L. DIAMOND,
LAWRENCE C. LEVINE & ANITA BERNSTEIN, UNDERSTANDING TORTS 93-94 (4th
ed. 2010) (explaining that the standard of care for professionals must be
placed in context of the profession and the courts defer to the expertise of the
profession for that custom); Hooks SuperX, Inc. v. McLaughlin, 642 N.E.2d
514, 517 (Ind. 1994) (imposing a professional standard of care on pharmacists
based on the reliance relationship between the expert pharmacist and the
patient, not shielded under the learned intermediary doctrine); see Horner v.
Spalitto, 1 S.W.3d 519, 523 (Mo. App. 1999) (determining that pharmacists
should not act as robots in dispensing prescriptions, but are in reality
professionals that should act according to a professional standard of care); see
Klasch v. Walgreen Co., 264 P.3d 1155, 1160 (Nev. 2011) (upholding the
learned intermediary doctrine protection for generalized risks, but holding
that pharmacists are not insulated by the learned intermediary doctrine when
the pharmacist has patient-specific knowledge).
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systematic way that a group handles particular situations.24 This
would mean that if a plaintiff could show that it is customary for a
pharmacist to always act in a specific way so as not to create an
unreasonable risk of harm, and the defendant pharmacist did not
act in that way, this failure may constitute a breach of the
pharmacist’s professional duty.
Alternatively, or in conjunction with custom, the standard of
care can be shown through professional rules of conduct for that
particular profession.25 Although these professional rules do not
always constitute a duty that the professional must legally abide
by, courts sometimes do find this plausible and impose such a
duty.26
Historically, a duty to warn has not been included in the
pharmacists’ standard of care when drug interactions are
considered27—in spite of the customs and rules of conduct/ethics
that exist for pharmacists.28 A drug interaction is defined as “an
interaction between a drug and another substance that prevents
the drug from performing as expected. This definition applies to

24. See BLACK’S LAW DICTIONARY 442 (9th ed. 2009) (defining custom as
“[a] practice that by its common adoption and long, unvarying habit has come
to have the force of law”); see also RESTATEMENT (SECOND) OF TORTS § 299A
cmt. e (1965) (stating the custom for the purposes of professional negligence is
the skill and knowledge that is “commonly possessed by members of that
profession or trade in good standing”).
25. See Marc R. Greenough, The Inadmissibility of Professional Ethical
Standards in Legal Malpractice Actions After Hizey v. Carpenter, 68 WASH. L.
REV. 395, 398-99 (1993) (stating that jurisdictions take different approaches in
the legal malpractice context, but that some jurisdictions do allow professional
ethical standards to create the standard of care). This general rule may be
extended to pharmacist malpractice as well.
26. See id. (explaining how some jurisdictions have applied professional
codes of conduct in ascertaining the standard of care); see also MODEL RULES
OF PROF’L CONDUCT Preamble & Scope [20] (2011) (stating that the rules do
not inherently establish a duty, however, “since the rules do establish
standards of conduct by lawyers, a lawyer’s violation of a Rule may be
evidence of a breach of the applicable standard of conduct”). Although this is
the legal context, the same premise spans professions. For each profession
there is generally some code of ethics or conduct that the professional is
expected to meet. Even though this code itself may not impose such a duty on
the professional, the custom that is created out of this code very well could be
the imposition of a duty on the professional.
27. Porto, supra note 9, at § 2(a); Johnson v. Walgreen Co., 675 So.2d 1036,
1037 (Fla. Dist. Ct. App. 1996). Like the Florida court in Johnson, the small
group of jurisdictions that have discussed whether a duty to warn of drug
interactions should be imposed on pharmacists have declined to impose such a
duty. The pharmacist only needs to fill the prescription accurately with due
care. Johnson, 675 So.2d at 1037.
28. See AphA-ASP/AACP COD, supra note 7, at 101 (replicating the
Commentary on Oath of a Pharmacist in which it states that the pharmacist
embraces a covenantal relationship with patients, yet courts have repeatedly
not applied a duty to warn of dangerous drug interactions).
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interactions of drugs with other drugs (drug-drug interactions) . . .
.”29 Additionally, the pharmacist is shielded from the duty to warn
under the learned intermediary doctrine.30
B. The Learned Intermediary Doctrine Shielding Pharmacists
and the Exceptions to the General Rule
According to the learned intermediary doctrine, doctors are
responsible to the patient for injuries caused by the medication the
doctor prescribed.31 The doctor has the duty to ensure there are no
interactions with the medications they are prescribing to the
patient.32 The learned intermediary doctrine originally protected
drug manufacturers from liability from a failure to warn
patients.33 Now the learned intermediary doctrine shields
pharmacists, like drug manufacturers, from the duty to warn.34
Proponents of shielding pharmacists under the learned
intermediary doctrine advance three primary arguments. First,
proponents of the learned intermediary doctrine argue that the
physician prescribing the medication is in the best position to
know the medical history and current condition of the patient, so
the liability should not fall on the pharmacist.35 In determining
this, courts reasoned that it was an unreasonable burden to
impose a duty to warn on pharmacists, and that it was against
public policy to expand liability to other health professionals.36
However, this Comment proposes it is entirely reasonable to
impose such a duty on pharmacists because they are trained to
spot drug interactions and have technology to further assist them

29. Omudhome Ogbru, Drug Interactions, MEDICINENET.COM (Jay W.
Marks ed.), http://www.medicinenet.com/drug_interactions/article.htm (last
visited Jan. 9, 2013).
30. See infra Part II(B) (discussing the learned intermediary doctrine and
how it has shielded pharmacists from a duty to warn patients).
31. Jennifer L. Smith, Comment, Between a Rock and a Hard Place: The
Propriety and Consequence of Pharmacist’s Expanding Liability and Duty to
Warn, 2002 HOUS. J. HEALTH L. & POL’Y 187, 194 (2002). “[A] manufacturer’s
duty to provide an adequate warning of the dangers associated with a drug
runs only to the physician.” Id.
32. See id. (determining in part that the doctor is in the best position to
know the specifics of the patient’s medical history and needs and thus the
doctor should be the one to decide the appropriate medication and warn the
patient if needed in the doctor’s discretionary opinion).
33. Id.
34. See Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1127 (Ill. 2002)
(electing to follow the underlying reasons for the learned intermediary
doctrine by allowing the pharmacist to contact the physician with drug
interaction information).
35. Id.
36. Bob Neiner, Casenote, A New Cure for Contraindication: Illinois
Supreme Court Prescribes a Duty to Warn on Pharmacists: Happel v. Wal-Mart
Stores, Inc., 766 N.E.2d 1118 (Ill. 2002), 28 S. ILL. U. L. J. 483, 487-88 (2004).
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in this task.37
Second, proponents of the learned intermediary doctrine
argue that finding otherwise would inject the pharmacist into the
doctor-patient relationship.38
Courts have refrained from
imposing a duty on the pharmacist citing this concern.39 Although
the doctor-patient relationship is important, the pharmacistpatient relationship is significant as well. As described later, there
is a “covenantal relationship”40 embraced by pharmacists, creating
trust between the patient and pharmacist.41 If pharmacists do not
warn patients of potentially deadly drug interactions, pharmacists
will not be as trusted and the relationship between patient and
pharmacist will suffer.
Third, proponents have argued that allowing claims against
pharmacists would allow the injection of non-diverse pharmacists
into lawsuits solely to prevent removal to federal courts based on
diversity jurisdiction.42 Although this may be true, this issue is not
unique to pharmacist defendants.43 Issues of “misjoinder” or
“fraudulent joinder” could occur with all types of claims and
defendants.44 Thus, it is not a valid objection only to claims
against pharmacists, and it prompts a broader legal discussion,
which is not encompassed in this Comment. The mere potential for
improper joinder should not bar a claim against a wrongdoer
absent other problems with the claim.
If an injury occurs from the medication that the doctor
prescribes, but the pharmacist accurately filled the prescription,
then the doctor may be civilly liable, but the pharmacist is
shielded from liability under the learned intermediary doctrine.45
37. Baker, 544 N.W.2d at 731; Cacciatore, supra note 16, at 104; see also
infra note 119 and accompanying text (explaining the pharmacist assumes a
duty to warn by advertising he will use a computer system to check for drug
interactions).
38. See Happel, 766 N.E.2d at 1127 (declining to impose a duty on the
pharmacist that would “interject himself into the doctor-patient relationship . .
. .”).
39. Id.
40. AphA-ASP/AACP COD, supra note 7, at 101; see also infra note 153-56
(explaining the importance of the conventional patient-pharmacist
relationship, pharmacist’s code of ethics, and how it may be undermined).
41. See GALLUP POLL, infra note 70 (explaining how highly pharmacists
are trusted as opposed to other professionals).
42. Jim Beck, Pharmacists and the Learned Intermediary Rule, DRUG AND
DEVICE DRUG L. BLOG (Feb. 24, 2011), http://druganddevicelaw.blogspot.com/
2011/02/pharmacists-and-learned-intermediary.html.
43. Paul Rosenthal, Improper Joinder: Confronting Plaintiffs’ Attempts to
Destroy Federal Subject Matter Jurisdiction, 59 AM. U. L. REV. 49, 50-52
(2009).
44. Id.
45. See Kirk v. Michael Reese Hosp. and Med. Ctr., 513 N.E.2d 387, 399
(Ill. 1987) (deciding for the first time, by the Supreme Court of Illinois, that
the learned intermediary doctrine shields drug manufacturer’s from the duty
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In fact, courts have determined that if there is a duty to warn at
all, it is to warn the physician of the drug interaction and not the
patient.46
In limited circumstances, however, the view of the pharmacist
and his duties to his patients has been changing, bringing it in
conflict with the traditional notions of the protections under the
learned intermediary doctrine. There are now particular
exceptions47 to the notion that the pharmacist has few duties, if at
all, owed to the patient. Some states now recognize exceptions
when the pharmacy assumes the duty to warn of potential drug
interactions.48 Usually, this is because the pharmacy has
advertised that it has a computer system to check for drug
interactions.49 Therefore, the pharmacy assumes the duty to check
for drug interactions, and not doing so qualifies as a breach of that
assumed duty.50 Another exception arises when the pharmacist
has special knowledge that would prevent a dangerous

to warn); see also Cottam v. CVS Pharm., 764 N.E.2d 814, 821 (Mass. 2002)
(extending the learned intermediary doctrine to pharmacists and establishing
there is no general duty to warn imputed to a pharmacists); Leesley, 518
N.E.2d at 763 (expanding the Kirk decision where the court determined that
the pharmacist was also protected under the learned intermediary doctrine).
Even though Cottam is about side effects instead of drug interactions, many
courts have since used this seminal case for the proposition that the
pharmacist has no general duty to warn. See Deed v. Walgreen Co., 927 A.2d
1001, 1003 (Conn. 2007) (invoking the learned intermediary doctrine in
defense of pharmacy when the pharmacy had no special knowledge that drugs
being taken would result in a toxic interaction); see also Hand v. Krakowski,
89 A.D.2d 650, 650 (N.Y. 1982) (stating that it was an issue of fact for the jury
to determine if the pharmacist had breached his professional duty in filling a
prescription that interacted with alcohol when the pharmacist had special
knowledge that the patient was an alcoholic).
46. DiGiovanni v. Albertson’s, Inc., 940 N.E.2d 73, 77 (Ill. App. Ct. 2010);
see also Happel, 766 N.E.2d at 1122 (explaining that when the pharmacist
knew or should have known of an interaction between the prescribed drug and
a known allergy, the pharmacist had a duty to either warn the physician or
the patient, despite the learned intermediary doctrine). Contra Silves v. King,
970 P.2d 790, 794 (Wash. App. Ct. 1999) (determining that the pharmacist has
no duty to warn the patient, not even a duty to warn the physician of a clear
drug interaction).
47. Neiner, supra note 36, at 495. For instance, in Illinois, there are four
factors that courts take into consideration when determining if a duty should
exist, thus carving out an exception under the learned intermediary doctrine.
Id. These four factors are: “(1) the reasonable foreseeability of harm; (2) the
likelihood of an injury occurring; (3) the magnitude of the burden; (4) the
consequences of imposing a duty on pharmacists.” Id.
48. Baker, 544 N.W.2d at 731 (deciding that when a pharmacy advertises
that its computer system will detect drug interactions, the pharmacy assumes
the duty to warn the patient of drug interactions, and is therefore not shielded
by the learned intermediary doctrine).
49. Id.
50. Id.
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interaction.51 Much of the movement to impose new duties on
pharmacists started with the federal Omnibus Budget
Reconciliation legislation in the 1990s52 and with the changing
role of the pharmacist in the United States.53
C. The Changing View of Pharmacists’ Roles and Duties
The Omnibus Budget Reconciliation Act of 1990 (hereinafter
“OBRA”) legislation imposes a duty on pharmacists with respect to
Medicaid subscribers.54 Among other things, this legislation
mandates Medicaid subscribers must be consulted by pharmacists
about the medication they receive at a pharmacy and screened for
potential drug interactions between prescribed drugs.55 As a

51. See Bobay v. Walgreen Co., 2009 WL 1940727 (Ind. Dist. Ct. 2009)
(stating no duty imposed on the pharmacist was established, but the court did
not foreclose the possibility that under different circumstances, where the
pharmacist had specific knowledge of the other prescriptions that may cause
an interaction, that the duty to warn of the drug interaction would be imposed
on the pharmacist); see also Brienze v. Casserly, No. 01-1655-C, 17
Mass.L.Rptr. 214 (Mass. 2003) (stating that because the pharmacy had filled
both prescriptions within days of each other, and there was in fact a known
direct interaction, the pharmacy had a duty to warn of the potentially
dangerous interaction).
52. Omnibus Budget Reconciliation Act of 1990, Pub. L. No. 101-508, 104
Stat. 1388. See discussion infra Part II(B).
53. See infra notes 61-68 and accompanying text (giving explanations
about the way the roles have changed).
54. 104 Stat. at 1388; see also Kenneth R. Baker, The OBRA 90 Mandate
and its Developing Impact on the Pharmacist’s Standard of Care, 44 DRAKE L.
REV. 503, 503 (1996) (explaining the provisions in OBRA that affect
pharmacists and Medicaid patients, including the responsibility of counseling
patients, part of which is looking for adverse reactions and interactions with
the prescribed drug).
55. Cacciatore, supra note 16, at 110-12. OBRA imposed upon states the
requirement of creating state legislation to comply with OBRA. Id. This
included the creation of the drug use review (“DUR”) program to ensure that
the drugs prescribed were medically necessary and that they were in fact
working how they were supposed to work. Id. The DUR program included an
educational aspect. Id. Pharmacists were required to screen for potential
problems with the drug prescribed, including looking for drug interactions. Id.
OBRA also required pharmacists to offer patient consultations related to the
prescribed drug. Id. This provision is often referred to as the “offer to counsel”
provision. Id.; see also Jesse C. Vivian & Joseph L. Fink III, OBRA ‘90 at
Sweet Sixteen: A Retrospective Review, U.S. PHARM., Mar. 20 2008,, at 59-65,
available at http://www.uspharmacist.com/content/d/featured_articles/c/10126/
(explaining that different states interpreted the need to counsel patients
under OBRA in different ways, some deciding that the counseling session had
to be conducted in-person while others stated that in-person consultation was
not necessary); OBRA 90 Mandated Drug Use Review (DUR), IDAHO STATE
UNIVERSITY
COLLEGE
OF
PHARMACY,
available
at
http://idahodur.isu.edu/mission.html (last visited Oct. 21, 2011) (stating that
one of the College’s missions is to abide by and improve the drug review
process, and that specialized computer systems are integrated into this
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matter of reference in the OBRA legislation, it mentions the
Drugdex System as an acceptable system for pharmacies to use in
order to check for drug interactions.56
Even though OBRA mandates technically apply to Medicaid
patients only, most states have instituted the same policies across
all patient groups.57 For this reason, pharmacies have patient
counseling windows where the pharmacist can ask whether a
patient has any allergies or questions regarding the prescribed
medication.
Although OBRA appears to place additional “duties” on
pharmacists, it does not actually allow for a private right of action
in accordance with these “duties.”58 Thus, OBRA was not the
solution to impose a duty to warn on pharmacists for which there
would be civil liability for the breach of that duty.59 Instead, OBRA
has fallen out of the spotlight, especially with state regulation
largely overshadowing the federal mandates.60
In addition to OBRA, the pharmacist’s role has changed
greatly to be more patient-oriented.61 In the 1920s, pharmacists
had to mix over eighty percent of all prescriptions.62 By 1974, that
number dropped to only one percent.63 Over the years,
pharmacists’ duties have shifted, becoming more in line with
patient issues.64
The pharmacist’s role has changed both through outside
legislation and from within the profession itself.65 While OBRA

process to ensure effectiveness); Strengthening the Texas Medicaid Drug
Utilization Review Program, HEALTH AND HUMAN SERVS. COMM’N (Dec. 2009),
http://www.hhsc.state.tx.us/reports/Rider49_MedicaidDrug_1209.pdf
(analyzing the Texas mandates and how the program in that state resulted in
revenue cost savings).
56. OBRA, 42 U.S.C. § 1396r-8 (2006); Products and Services, Drugdex
DISCOVERY
ONLINE,
System,
DRUG
http://www.drugdiscoveryonline.com/product.mvc/Drugdex-System-0001 (last
visited Jan. 9, 2013).
57. South Carolina Pharmacy Practice Act, S.C. CODE ANN. § 40-43-88
(1976); Wyoming Pharmacy Act, WYO. STAT. § 33-24-9 (2002); OR. REV. STAT.
§ 414.385 (2009).
58. See Kowalski v. Rose Drugs of Dardanelle, Inc., No. 10-459, 2011 Ark.
44, *12 (Ark. 2011) (failing to impose a private right of action under OBRA);
see also Johnson v. Badger Acquisition of Tampa LLC, 983 So. 2d 1175, 1182
(Fl. Dist. Ct. App. 2008) (finding that OBRA did not create a private cause of
action).
59. Omnibus Budget Reconciliation Act of 1990, Pub. L. No. 101-508, 104
Stat. 1388.
60. See supra note 55 (explaining state regulations that emerged in
compliance with OBRA).
61. Cacciatore, supra note 16, at 104.
62. Id.
63. Id.
64. See AphA-ASP/AACP COD, supra note 7, at 96.
65. See Cacciatore, supra note 16, at 104 (explaining that the pharmacy
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and state legislation have mandated specific changes to the
pharmacist’s role, internally in the pharmacy profession there has
also been a change.66 Marketing strategies are now focused on the
pharmacist’s relationship with the patient.67 Additionally, young
pharmacists are now learning about the “advanced patient care
objective” in pharmacy school,68 with some schools even
participating in patient-counseling competitions.69
The enhanced communication and relationship between
pharmacists and patients has created more reliability on
pharmacists to warn patients of various dangers.70 Meanwhile, the
pharmacist still does not have a legal duty to warn the patient of
drug interactions,71 even though pharmacists often have
knowledge of potential interactions and are taught to notify
patients of such interactions.
While the changing role of pharmacists has potentially
opened pharmacists up to additional liability, they are still
protected under the learned intermediary doctrine.72 Because of
this, the burden to warn patients of drug interactions continues to
fall on the prescribing physician.

profession has become more patient oriented).
66. Id.
67. Id.
68. Id.; see also Mark R. Amsler et al., Pharmaceutical Care in Chain
Pharmacies: Beliefs and Attitudes of Pharmacists and Patients, J. AM. PHARM.
ASSOC., 2001 (explaining the expanded roles of pharmacists as providers of
“pharmaceutical care” and not merely dispensers of drugs).
69. American Pharmacists Ass’n, AphA-ASP National Patient Counseling
http://www.pharmacist.com/apha-aspCompetition,
PHARMACIST.COM,
national-patient-counseling-competition (last visited Jan. 9, 2013) [hereinafter
Patient Counseling Competition]. The competition focuses on the “art of
patient counseling,” where students counsel patients “on the safe and effective
use of a medication after consulting drug information resources and a patient
medication profile.” American Pharmacists Ass’n, 2013 AphA-ASP National
Patient
Counseling
Competition,
PHARMACIST.COM,
http://www.pharmacist.com/sites/default/files/files/NPCC%20Poster%202013.p
df (last visited Jan. 9, 2013).
70. See GALLUP POLL, HONESTY AND ETHICS OF PROFESSIONS (2009),
available
at
http://www.gallup.com/poll/124625/honesty-ethics-poll-findscongress-image-tarnished.aspx (demonstrating that patients trust and rely on
pharmacists more than other professions); see also Cacciatore, supra note 16
(explaining the changing role of the pharmacist to be more patient-oriented).
71. Happel, 766 N.E.2d at 1127; Leesley v. West, 518 N.E.2d 758, 763 (Ill.
App. 1988).
72. Happel, 766 N.E.2d at 1127; Leesley, 518 N.E.2d at 763.
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III. ANALYSIS
Pharmacists have unique responsibilities and knowledge.73
Because of these special skills, they are trusted with dangerous
drugs.74 As professionals, pharmacists must adhere to the custom
in their profession.75 Although pharmacists may act negligently
when dispensing prescription drugs that may interact with other
drugs or conditions, they are shielded by the learned intermediary
doctrine.76 Thus, pharmacists have no duty to warn patients of
drug interactions.
A. Pharmacists as Professionals
Pharmacists, like many professional professions,77 have
special education and training requirements.78 Because of their
special knowledge and training, pharmacists are not laypeople,
but are professionals held in a position of trust.79 When a
professional has specific knowledge that other people do not have,
ordinary people trust these professionals to exercise this special
knowledge on their behalf.80 In fact, pharmacists are one of the
most trusted types of professionals.81 Less trusted professionals
included medical doctors, engineers, and lawyers, all of which have

73. See BUREAU OF LABOR STATISTICS, supra note 5, at 1 (explaining that
pharmacists must have specific knowledge, degrees, and must pass tests to
show they are competent in unique areas of pharmacy).
74. Id. (explaining that pharmacists must have specific knowledge,
degrees, and must pass tests to show they are competent in unique areas of
pharmacy).
75. See DIAMOND, LEVINE, & BERNSTEIN, supra note 23, at 93-94
(explaining that professionals are held to a standard of care, usually expressed
through custom).
76. Leesley, 518 N.E.2d at 763.
77. See infra note 82 (explaining instances in which different types of
professionals were held to a heightened professional standard of care).
78. See BUREAU OF LABOR STATISTICS, supra note 5, at 1 (explaining that
pharmacists must now complete a six year program and be licensed in each
state where they wish to practice).
79. BLACK’S LAW DICTIONARY 414 (9th ed. 2009) (defining layperson as “a
person who is not a member of a profession or an expert on a particular
subject”); see also GALLUP POLL, supra note 70 (stating that pharmacists are
one of the most trusted professionals, second only to nurses). See Lynda
Jensen, Pharmacists: A Matter of Trust, HERALD JOURNAL, http://www.heraldjournal.com/health/pages/previous/trust.html (last visited Jan 9, 2013) (noting
that pharmacists are one of the most trusted professionals because they are
often an easy way to get access to a health care professional in order to obtain
unbiased opinions about drugs and medical conditions). The article also points
out that communication and individualized relationships with the patients are
main motivators in trusting pharmacists. Id.
80. GALLUP POLL, supra note 70.
81. Id. The Gallup poll reported that sixty-six percent of Americans
thought that pharmacists had very high/high honesty and ethical standards.
Id.
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been held to a professional standard of care.82
B. Custom Establishes the Professional Standard of Care
For a plaintiff to establish a prima facie case for negligence,
he must show that the defendant acted in a manner not in
conformity with the duty owed and caused the plaintiff’s injuries.83
To do so, the plaintiff must establish that the defendant’s conduct
fell below the applicable standard of care.84 For a professional, the
standard of care would be to act as a reasonably prudent
professional.85
The standard of care may be established through various
means, but usually for a professional, it is established through
custom.86 Thus, if a plaintiff could prove that a specific custom
existed in the profession, then that custom may be used to
establish the duty. By proving that the professional did not adhere
to the custom, the plaintiff could show a breach of the duty.87
To prove that a custom exists, expert witnesses are used in a
testimonial capacity.88 Each expert would present to the court
82. Id. Among the lowest ranked professions were medical doctors,
engineers, and lawyers. Id. All these professionals have been held to a
professional standard of care in various cases. See Broadway v. Bay Hosp.,
Inc., 638 So. 2d 176, 177 (Fla. 1st Dist. App. 1994) (stating that the medical
malpractice case must be proved by showing that the professional standard of
care was not met); see also Chapman v. Bearfield, 207 S.W.3d 736, 739 (Tenn.
2006) (applying the professional standard of care statewide to lawyers in
Tennessee); Ahimsa Technic, Inc. v. Lighthouse Shores Town Homes Dev. Co.,
543 So. 2d 422, 422 (Fla. 5th Dist. App. 1989) (upholding the finding that the
engineer did comply with the professional standard of care of engineers);
Hous. Auth. of City of Carrollton v. Ayers, 88 S.E.2d 368, 373 (Ga. 1955)
(stating architects are held to the professional standard of care); Allied
Enters., Inc. v. Brooks, 93 S.E.2d 392, 397 (Ga. App. 1956) (imposing
professional standard of care on building contractors); Coyne & Delany Co. v.
Selman, 98 F.3d 1457, 1472 (4th Cir. 1996) (stating that the professional
standard of care is applicable to an employee benefit company that had
negligently designed and administered group health plans); Lewis v.
Rodriguez, 759 P.2d 1012, 1016 (N.M. App. 1988) (holding that polygraphers
are professionals that are subject to the professional standard of care).
83. See 57A AM. JUR. 2D Negligence § 71 (laying out the elements needed
for a negligence action, including breach of a duty).
84. Horner v. Spalitto, 1 S.W.3d 519, 522 (Mo. Ct. App. 1999) (discussing
pharmacists are a professionals who should be held to the professional
standard of care); S.Y. TAN, MEDICAL MALPRACTICE – UNDERSTANDING THE
LAW, MANAGING THE RISK 37 (2006).
85. Horner, 1 S.W.3d at 522; TAN, supra note 84.
86. See RESTATEMENT (SECOND) OF TORTS § 299A cmt. e (1965) (explaining
that the custom is the accepted practice in the profession).
87. See Owen, supra note 22, at 1673-74 (stating that breach of duty is the
second element for a cause of action in a negligence case).
88. TAN, supra note 84, at 38. Experts are helpful in establishing the
custom because they too have the required knowledge, schooling, and
experience that one in the profession has as well. Id. Most often both the
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evidence that he or she is part of the particular profession of the
defendant in the negligence case.89 The expert would then present
evidence, often with the aid of authoritative evidence, as to what
the standard of care is in that particular profession.90
For example, in medical malpractice cases, the expert witness
would also be a doctor in the same specialty as the defendant and
would testify to the accepted practice among doctors in that
specialty.91 If the defendant did not act in accordance with the
customary practice of doctors described by the expert, then it is
likely that the jury would find that the doctor breached the duty
and was therefore negligent.
Just as in the medical malpractice context, pharmacists are
also professionals who should be expected to adhere to the
professional standard of care.92 As such, expert witnesses would
testify to the pharmacy industries’ customs. Then the jury would
decide if the pharmacist adhered to the applicable standard or
breached his duty. In the scenario discussed here, an expert would
be used to demonstrate that the custom in the pharmacy
profession is to warn the patient when a drug interaction is
possible. When the pharmacist does not warn the patient of an
interaction, the pharmacist breaches the duty to warn and may be
liable in a negligence action.
Alternatively, a plaintiff may establish the standard of care in
other ways. The standard of care may also be established through
common knowledge,93 statutes,94 or the profession’s code of
plaintiff and the defendant present their own expert witnesses to establish the
custom. Id. Thus, if more than one custom is proposed, it is up to the factfinder, most likely a jury, to decide which expert to believe. Id.
89. Id.
90. Id.
91. See Perdieu v. Blackstone Fam. Prac. Ctr., Inc., 568 S.E.2d 703, 709-10
(Va. 2002) (asserting that an expert witness was needed to establish the
custom and that the expert used here was not qualified to the same specialty
because he did not have specific experience in nursing homes); see also Coston
v. Bio-Med. Applications of Virginia, Inc., 654 S.E.2d 560, 562 (Va. 2008)
(articulating that while there are some rare circumstances in which an expert
is not needed because common knowledge would suffice, in most situations
expert testimony is needed to establish the custom). Although the example in
the text of the article is that of medical malpractice, the same basic theory is
used for all professions in professional negligence actions. Id. For instance,
expert testimony was needed in a professional negligence case against an
electrical contractor because the information was technical and the complexity
of the information was not suitable for an ordinary (lay) juror to understand
without the aid of expert testimony as to the standard of care. Midwest Iron &
Metal, Inc. v. Zenor Elec. Co., Inc., 19 P.3d 181, 183-84 (Kan. App. Ct. 2000).
92. See generally supra Part III(a) (explaining that pharmacists are
professionals).
93. See Leonard v. Watsonville Cmty. Hosp., 305 P.2d 36, 42 (Cal. 1956)
(explaining that leaving operating instruments in a patient’s abdomen during
a medical procedure is so obviously negligent that it is common knowledge to
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ethics.95
C. Impact of the Learned Intermediary Doctrine Extended to
Pharmacists and Its Implications on the Duty to Warn
Originally, the learned intermediary doctrine was created to
shield drug manufacturers from liability for failure to warn
patients of adverse side effects and interactions.96 The learned
intermediary doctrine may be invoked to absolve the drug
manufacturer of liability if it had provided warnings to the
prescribing physician.97 The responsibility, then, falls on the
physician to warn the patient of adverse side effects and
interactions. Under these rules, the patient must sue the
physician for recourse, and cannot sue the drug manufacturer.98

jurors and that no further evidence of the standard of care is required beyond
this common knowledge).
94. See Bryant v. Delmarva Power & Light Co., 1995 WL 653987 (Del. App.
1995) (stating that one of the ways in which the standard of care can be
established is through statutes); see also Bob Godfrey Pontiac, Inc. v. Roloff,
630 P.2d 840, 844 (Or. 1981) (considering the types of statutes that give rise to
the standard of care).
95. See Allen v. Lefkoff, Duncan, Grimes & Dermer, P.C., 453 S.E.2d 719,
722 (Ga. 1995) (articulating that the code of professional ethics that lawyers
follow may indeed be instructive on determining what the standard of care is
in a legal malpractice case).
96. See generally Marcus v. Specific Pharm., Inc., 77 N.Y.S.2d 508 (App.
Div. 1948) (embodying for the first time the rule that would later evolve into
the learned intermediary doctrine). The court held that the pharmaceutical
company did not have a duty to warn the patient of drugs that were available
only through the physician’s prescription). Id. at 510; Love v. Wolf, 38 Cal
Rptr. 183, 193 (Dist. Ct. App. 1964) (establishing for the first time the “no duty
rule,” which states that as long as the drug manufacturer warns the physician,
they have no further duty to warn the patients). The explicit reasoning behind
the “no duty rule” and the term “learned intermediary” came about two years
after the Love decision, in Sterling Drug, Inc. v. Cornish, 370 F.2d 82, 85 (8th
Cir. 1966). The reasoning was that because the drug was only available
through prescription, the liability and warning should be placed on the
prescribing physician to then convey the pertinent information to the patient.
Id.
97. Diane Schmauder Kane, Annotation, Construction and Application of
Learned Intermediary Doctrine, 57 A.L.R. 5TH 1 (1998); Paul M. Coltoff et al.,
To Whom Warnings Must be Provided: the Learned-Intermediary Doctrine, 28
C.J.S. Drugs and Narcotics § 128; Richard B. Goetz & Karen R. Growdon, A
Defense of the Learned Intermediary Doctrine, 63 FOOD & DRUG L.J. 421, 422
(2008); John A. Camp & Gary M. Pappas, The Learned Intermediary Doctrine
in Florida: Courts Wrestle with Claimed Exceptions to the Doctrine in Drug
and Device Litigation, 82 FLA. B.J. 8, 9 (Dec. 2008); Kyle T. Fogt, The Road
Less Traveled: West Virginia’s Rejection of the Learned Intermediary Doctrine
in the Age of Direct-to-Consumer Advertising, 34 J. CORP. L. 587, 590 (2009).
98. James Barney, Dancing Towards Disaster or the Race to Rationality:
The Demise of the Learned Intermediary Standard and the Pharmacists’ Duty
to Warn, 39 GONZ. L. REV. 399, 403-04 (2004).
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1. The History and Intent of the Learned Intermediary Doctrine
The learned intermediary doctrine was created to alleviate
the pressure on the drug manufacturing industry to warn patients
of the dangers of prescription medications.99 Because drugs are
inherently dangerous depending on medical condition, allergies,
dosage requirements, and interactions, the drug manufacturer
could be open to endless liability.100 Liability may impede the drug
manufacturers from continuing to research and create new drugs
that benefit patients.101 As such, there was a need to create a
defense to this endless liability, and thus the learned intermediary
doctrine was created.102 Under this doctrine, the liability would be
passed to the physician as long as the drug manufacturer warned
the physician.103
The learned intermediary doctrine also has the effect of
putting the information about the dangers of these drugs in more
capable hands.104 Physicians, as opposed to patients, know much
more about drugs, medical conditions, and drug therapy.105
Therefore, it was thought that the physicians are in a better
position than the patient to make an informed choice about drug
treatment methods.106 Despite the original intent, it has been
argued that the doctrine does not adequately protect patients and
that the purpose of the doctrine has become obsolete.107

99. In re Norplant Contraceptive Prods. Litig., 165 F.3d 374, 379 (5th Cir.
1999).
100. According to product liability theory, the drug manufacturer would be
liable for the failure to warn of the product’s dangers because the product is
unreasonably dangerous. Fogt, supra note 97, at 589.
101. See Goetz & Growdon, supra note 97, at 422 (explaining the rationale
behind the inception of the learned intermediary doctrine).
102. See Sterling, 370 F.2d at 85 (enunciating for the first time, the learned
intermediary doctrine).
103. Id.
104. Id.
105. Id.
106. McKee v. Am. Home Prods., Corp., 782 P.2d 1045, 1050 (Wash. 1989).
107. See Camp & Pappas, supra note 97, at 8 (discussing the recent changes
and exceptions to the learned intermediary doctrine); Stephen R. Kaufmann &
Jason D. Johnson, The Learned Intermediary Doctrine and Pharmaceutical
Company Liability, 95 ILL. B.J. 202, 206 (2007) (explaining that some
jurisdictions have created exceptions to the protection of the learned
intermediary doctrine in circumstances where the drug manufacturer directly
marketed the drug to consumers). This exception is called the direct-toconsumer-advertising/marketing exception. Id.; see also Perez v. Wyeth Labs.
Inc., 734 A.2d 1245, 1264 (N.J. 1999) (deciding not to allow the learned
intermediary doctrine to protect drug manufacturers when direct-to-consumer
advertising has occurred).
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2. Extension of the Learned Intermediary Doctrine to Pharmacists
Although the learned intermediary doctrine was originally
developed to shield drug manufacturers from liability, it has since
been extended to shield pharmacists from liability as well.108 In
extending the learned intermediary doctrine to pharmacists, it is
taking away a safety precaution in warning the patient of
potentially dangerous drug interactions. Thus, the physician is
truly the only safeguard left to stop a potentially deadly drug
interaction that a patient may know nothing about and for which
he is never given notice. In doing this, the patient is also kept in
the dark, unable to make his own decisions about his healthcare
treatment and the potential risks.
Interference with the doctor-patient relationship has been
cited as the primary concern that could arise from shielding
pharmacists from liability under the learned intermediary
doctrine.109 Proponents of that approach worry that opening
pharmacists up to liability will encourage pharmacists to secondguess doctors.110 Also, others argue that pharmacists usually
collect patient information to flag possible problems with a
prescription, but that if pharmacists were opened up to liability
based on the information they collect, they will stop gathering
patient information, therefore depriving patients of an important
service.111 Additionally, it is argued that doctors are in the best
position to know which prescriptions the patient is on and which
ones to prescribe at any given time.112 However, pharmacists are
108. Barney, supra note 98, at 404. In re New York Cnty. Diet Drug Litig.,
691 N.Y.S.2d 501, 502 (N.Y. App. Div. 1st Dept. 1999) (deciding that
pharmacists are shielded by the learned intermediary doctrine); Ramirez v.
Richardson-Merrell, Inc., 628 F. Supp. 85, 87 (E.D. Pa. 1986) (stating that the
court will not impose a duty to warn the patient in this case because it does
not think the pharmacist should have a duty when the drug manufacturer
does not. The drug manufacturer in this case, of course, does not have a duty
because it is shielded under the learned intermediary doctrine. Thereby this
case illustrates the court taking a round-about way of extending the learned
intermediary doctrine to pharmacists.); Jones v. Irvin, 602 F. Supp. 399, 402
(S.D. Ill. 1985) (stating again that it is the physician’s responsibility to warn
the patient of drug interactions, or adverse side effects, and not the
pharmacist); Silves, 970 P.2d at 794 (nothing that there is no duty to warn
imposed on the pharmacist because it would interject the pharmacist into the
doctor-patient relationship. Instead, the duty is placed on the physician to
warn the patient.); Johnson 675 So. 2d at 1038 (imposing the duty to warn on
the physician instead of the pharmacist); McKee, 782 P.2d at 1050 (extending
the learned intermediary doctrine to pharmacists).
109. See supra note 36 and accompanying text (discussing the main reasons
why pharmacists have remained under the learned intermediary doctrine,
specifically citing the importance of the doctor-patient relationship in Happel,
766 N.E.2d at 1124).
110. Jones, 602 F. Supp. at 402.
111. Happel, 766 N.E.2d at 1124.
112. Id. at 1126.
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trained specifically in prescription medication.113 Thus, it is logical
that pharmacists actually know much more about specific drugs
and their interactions with other drugs than a doctor normally
would. As discussed later, shielding pharmacists under the
learned intermediary doctrine does not best serve patients and is
contrary to the oaths pharmacists have sworn to uphold.114
3. Exceptions to the Learned Intermediary Doctrine Shielding
Pharmacists from Liability
Currently, the majority of jurisdictions extend the learned
intermediary doctrine to pharmacists, finding that they are not
liable in negligence actions, despite acting negligently.115 Some
jurisdictions do allow for certain limited exceptions, taking the
case out from under the safeguard of the learned intermediary
doctrine, and finding possible liability instead.116 Most of these
exceptions, however, came about because of adverse drug side
effects about which the pharmacist did not warn the patient.117
Some exceptions have been applied, or have the possibility of being
applied, in instances of a pharmacist’s failure to warn of drug
interactions as well.118
a. Assumed Duty to Warn
One such instance is when the pharmacy assumes the duty to
warn.119 This usually happens in the context of a pharmacy
113. Horner, 1 S.W.3d at 523.
114. See Happel, 766 N.E.2d at 1127 (explaining the traditional reasons to
shield pharmacists from liability under the learned intermediary doctrine with
responses to such reasons); see also infra notes 150, 154, 167 and
accompanying text (proposing that pharmacists’ roles, codes of ethics and
custom already establish that pharmacists seek to prevent drug interactions
and should not be protected under the learned intermediary doctrine any
longer).
115. McKee, 782 P.2d at 1050; Cottam, 764 N.E.2d at 821; Leesley, 518
N.E.2d at 762; Jones, 602 F.Supp. at 399; Ramirez, 628 F.Supp. at 88;
Eldridge v. Eli Lilly & Co., 485 N.E.2d 551, 552-53 (1985); Batiste v. Am.
Home Prods. Corp., 32 N.C.App. 1, 231 S.E.2d 269, 274 (1977).
116. See supra Part II(B), with emphasis on cases in note 46 (explaining the
limited circumstances in which courts have determined there may be a duty
imposed on pharmacists regardless of the learned intermediary doctrine).
117. See generally supra note 45 (most cases arise from some kind of side
effect and not from a drug interaction).
118. Happel, 766 N.E.2d at 1127 (applying partial responsibility on the
pharmacist to warn of drug interactions, but falling short of imposing an
affirmative duty on the pharmacist to notify the patient of drug interactions).
119. See 57A AM. JUR. 2D Negligence § 193 (describing the “assumed-duty
doctrine” as that which imposes the duty voluntarily assumed to not act
negligently in performing the duty and asserting that the person that assumes
the duty may be liable in a negligence action if he breaches that assumed
duty).
To apply the doctrine, the defendant must have (1) acted in an
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advertising that its computer system will check for drug
interactions.120 When such a situation occurs, then the duty to
warn is imputed on the pharmacy to use those mechanisms to
check for drug interactions and to warn the patient if one is
found.121 Of course, this also means that the pharmacy implicitly
takes on the duty to properly use the mechanism to check for these
possible interactions.
b. Personal Knowledge Creates a Duty to Warn
Another instance is the personal knowledge exception.122 This
exception allows the plaintiff to bring a negligence action against
the pharmacist when the pharmacist has actual, personal
knowledge of a condition in which a drug interaction is blatantly
apparent.123 Such an instance has been upheld when the
pharmacist had actual knowledge that the patient was an
alcoholic and that the drug prescribed would adversely interact
with alcohol.124 Another example is when the pharmacist actually
knew that the patient’s allergy would interact with the prescribed
drug and filled the prescription anyway, without warning the
patient.125

affirmative way or through a promise to act, undertook to render a
service that was reasonably calculated to prevent the type of harm that
befell the plaintiff; and either (2) that the plaintiff relied on the
defendant to perform the service; or (3) that defendant’s undertaking
increased plaintiff’s risk.
Wark v. U.S., 269 F.3d 1185, 1189 (10th Cir. 2001). See Baker, 544 N.W.2d at
730 (stating that the pharmacy assumed the duty to warn of drug interactions
when it advertised its computer system that checks for these interactions);
Cottam, 764 N.E.2d at 821 (indicating that the defendant pharmacy assumed
the duty to warn when it warned the patient of some side effects but not
others).
120. See Baker, 544 N.W.2d at 730-31 (deciding that the learned
intermediary doctrine does not apply when the pharmacy assumes the duty to
warn the patient). This exception is a spin-off of the exception to the drug
manufacturer’s application of the learned intermediary doctrine with direct-toconsumer marketing. See also Charles J. Walsh, Steven R. Rowland & Howard
L. Dorfman, The Learned Intermediary Doctrine: The Correct Prescription For
Drug Labeling, 48 RUTGERS L. REV. 821, 875-77 (1996) (explaining that when
the drug manufacturer advertises its drug directly to the patient, they are no
longer shielded by the learned intermediary doctrine and have a duty to warn
the patient).
121. Baker, 544 N.W.2d at 729-31.
122. Hand, 453 N.Y.S.2d at 651.
123. Id.
124. Id.
125. Happel, 286 F. Supp. 2d at 947.
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4. The Learned Intermediary Doctrine as an Impediment to
Liability in Today’s Pharmacies
The fact is that many, if not all, pharmacies now have
software that check for drug interactions.126 The time has long
passed that pharmacists did all their work by hand. Now
pharmacies are highly computerized127 and almost all have
systems that specifically check for drug interactions.
Most drug interaction cases sounding in negligence, however,
are simply barred by the learned intermediary doctrine.128 The
learned intermediary doctrine is a significant impediment to
courts imposing a duty on pharmacists to warn patients of drug
interactions. Even with the limited exceptions to the learned
intermediary shield of liability, patients are still being injured and
are unable to recover from pharmacists’ negligence.
D. The Pharmacist’s Changing Role from Drug Dispenser to
Provider of Pharmaceutical Care
The role of the pharmacist has changed drastically in recent
years. While pharmacists’ duties were once exclusively to mix and
dispense drugs, the duties are now more patient oriented.129 Along
with OBRA,130 and each state’s legislation,131 the pharmacy
industry has internally changed its focus and image.132 In
commercials and other avenues of advertising, pharmacies hold
the profession out to patients as being patient oriented.133
Pharmacies often have patient consultation windows.134 Pharmacy
schools teach that the profession is one that is patient oriented.135
126. Ctr. for Med. & Healthy Aging, Drug Interactions, Steps You Can Take
To
Decrease
Your
Risk
of
Drug
Interactions,
available
at
http://www.medsandaging.org/DrugInteractions.htm (last visited Apr. 20,
2012).
127. Cacciatore, supra note 16, at 104.
128. Leesley, 518 N.E.2d at 763; Cottam, 764 N.E.2d at 821; Deed, 927 A.2d
at 1003.
129. Cacciatore, supra note 16, at 104.
130. See supra Part II(C) (explaining the OBRA legislation specifics).
131. See id. (articulating that states have expanded pharmacy laws beyond
what was required under OBRA).
132. See Am. Pharm. Assoc., Pharmacists Offer Guidance on Top Over-theCounter
Medications
(Apr.
25,
2011),
available
at
http://www.reuters.com/article/2011/04/25/idUS110518+25-Apr2011+PRN20110425 (stating that pharmacists should attempt to conduct
patient consults, and that on average they take merely three minutes).
133. AM. PHARM. ASSOC., USING RELATIONSHIP MARKETING TO EXPAND
PHARMACY
SERVICES
3
(2007),
http://www.pharmacist.com/sites/default/files/files/mtm_using_relationship_m
arketing.pdf.
134. Cacciatore, supra note 16, at 110-112.
135. AphA-ASP/AACP COD, supra note 7, at 101-102; Patient Counseling
Competition, supra note 69.
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This change in the view of the role of a pharmacy, both from the
outside and from within the profession, necessitate that
pharmacists take on additional responsibilities. With those
responsibilities come certain liabilities, one being the duty to warn
the patient of drug interactions.
No jurisdiction has gone as far as to find that there is an
unconditional duty to warn of drug interactions imposed on
pharmacists.136 The consequence, of course, is that the liability is
placed solely on physicians. Alternatively, if the patient cannot
bring a case against the physician for some reason or the case fails
at trial, then the patient has no recourse.137
For instance, when a plaintiff originally brought a claim
against multiple defendants, including doctors and the pharmacy,
summary judgment was entered favoring all but one doctor and
the hospital pharmacy.138 The remaining doctor settled for a
comparatively small amount while the trial continued for the
hospital pharmacy.139 At jury trial, the plaintiff received a jury
verdict of over four million dollars, but the appellate court
reversed, stating that the learned intermediary doctrine shielded
the pharmacy.140 Thus, the plaintiff was left with the small
settlement from one doctor with no further recourse.141 Surely
imposing a duty on the pharmacist to warn of drug interactions far
surpasses the original goals of the learned intermediary doctrine
applied to drug manufacturers, and is in line with the
pharmacists’ new patient oriented role.
IV. PROPOSAL
Pharmacists should have a duty to warn patients of drug
interactions and should not be shielded by the learned
intermediary doctrine. Further, to comply with this duty,
pharmacists should also have a duty to inquire as to whether a
drug interaction is present. It should not be tolerated when the
pharmacist notifies the physician about a drug interaction, the
physician does nothing, and the pharmacist nonetheless fills the

136. While no jurisdiction has explicitly adopted the view of this article, one
jurisdiction has come close. In Dooley v. Everett, 805 S.W.2d 380, 384-86
(Tenn. App. 1990), the court determined that the pharmacist should be held to
the professional standard of care, but that it was up to the jury to determine
whether there was in fact a duty to warn the patient of drug interactions.
137. See Springhill Hospitals, Inc. v. Larrimore, 5 So. 3d 513, 516 (Ala.
2008) (overturning a jury verdict of over four million dollars, stating that the
pharmacy was shielded by the learned intermediary doctrine).
138. Id.
139. Id. While the plaintiff and last remaining doctor settled for $200,000,
the original jury verdict included more than $4,000,000. Id.
140. Id. at 519.
141. Id. at 516.
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prescription without providing any warning to the patient.142 The
duty to warn the patient of drug interactions is established
through the custom of the profession and should not be abrogated
by the learned intermediary doctrine because pharmacists’ ethical
codes display intent to serve patients without a doctrinal shield.
A. Pharmacists’ Standard of Care Established by Custom
As professionals, pharmacists must be held to a professional
standard of care. This standard is determined by custom143 and
demonstrated through expert testimony.144 In the context of drug
interactions, an expert would need to testify that pharmacists
usually do check for drug interactions and inform the patient of
any such drug interactions.145
Once this is established, then the standard of care may be
compared to the actual conduct of the individual pharmacist to
show whether he complied with that standard or breached the
duty.146 The duty would be breached when the pharmacist either
did not check for any drug interactions or did not notify the patient
of any known drug interactions.
Due to the changing role of the pharmacy profession, it is
even more likely that an expert would testify to the fact that

142. See DiGiovanni, 940 N.E.2d at 77 (explaining that the pharmacist’s
duty to warn was fulfilled when the pharmacist warned the physician of the
drug interaction, even though the doctor did not decide to change the drug and
the interaction still occurred, severely harming the patient).
143. See RESTATEMENT (SECOND) OF TORTS § 299A cmt. e (1965) (explaining
that the custom is used to determine the standard of care for professionals).
144. See McKee, 782 P.2d at 1057 (articulating that the standard of care
where professional duties are concerned is often determined by the use of
expert witnesses, including in a pharmacist negligence action). “In general,
expert testimony is required when an essential element in the case is best
established by an opinion which is beyond the expertise of a layperson . . .
[t]hus, expert testimony will generally be necessary to establish the standard
of care . . . .” Id.
145. See Lasley v. Shrake’s Country Club Pharm., Inc., 880 P.2d 1129, 1134
(Ariz. App. 1st Div. 1994) (explaining that in this case experts were presented
to determine whether the pharmacist has a duty to warn established by
custom, such that there was a genuine issue of material fact, reversing the
summary judgment decision previously entered); see also Nail v. Publix Super
Markets, Inc., 72 So.3d 608, 616 (Ala. 2011) (determining that sufficient
expert testimony was presented to allude to the determination that the
pharmacist has a duty to counsel patients in order to detect potentially
dangerous drug interactions). See contra Bobay v. Walgreen Co., 2008 WL
3256368 (N.D. Ind. 2008), on reconsideration, 2009 WL 1940727 (N.D. Ind.
2009) (deciding that when no expert testimony from a pharmacist was offered
to establish the standard of care, no corresponding breach of a duty could be
shown and the defendant pharmacist was granted summary judgment).
146. See Owen, supra note 22, at 1673-74 (indicating that breach is one of
the required elements for a negligence action).
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pharmacists normally do warn patients of drug interactions.147 Not
only do pharmacists dispense drugs, but they also consult with
patients about the prescribed drugs, answer questions about
generic drugs, and help patients with over-the-counter medication
questions and choices.148 The statutory regulations149 for the
professional standards of ethics of pharmacists150 show a clear
duty to patients and a responsibility to ensure the patient’s
welfare in dispensing drugs.
Again, because most pharmacists now take on these new
responsibilities to patients, it is likely now considered custom in
the profession.151 Thus, if a pharmacist’s conduct does not adhere
to the custom of warning the patient of drug interactions, then a
breach of duty exists. Clearly, through the use of custom, courts
should impose on pharmacists a duty to warn patients of drug
interactions.
B. The Learned Intermediary Doctrine May Not Shield the
Pharmacist from Liability in Denial of the Pharmacists’ Code of
Ethics or Oath
Even if pharmacists have a professional duty established by
custom, the learned intermediary doctrine continues to shield
pharmacists from liability.152 This can no longer be tolerated.
Because both the general negligence principles and the
pharmacists’ professional standards of conduct, ethics, and oaths
147. See Your Pharmacist: A Partner in Drug Safety, PFIZER 1 (Oct. 2011),
http://www.pfizer.com/files/health/medicine_safety/4-4_Your_Pharmacist.pdf
(stating that “pharmacists are medication experts, checking each prescription
to help ensure that. . .the new medication will not interact with anything else
they know you are taking”). Going even further, Pfizer later states that “your
pharmacist is a resource and an educator for you and your family.” Id.
Additionally, Pfizer tells patients in its brochure to “[l]isten to the
pharmacist’s advice.” Id. at 2.
148. George Hradecky, The Evolving Role of the Pharmacist,
(Sept.
1,
2001),
Pharmaceutical
Representative,
SPECTROSCOPY
http://www.spectroscopyonline.com/
spectroscopy/article/articleDetail.jsp?id=113520; Your Pharmacist: A Partner
in Drug Safety, supra note 147, at 1; Cacciatore, supra note 16, at 104; see also
Patient Counseling Competition, supra note 69 (explaining that even students
participate in a competition naming the best student to perform patient
consultations).
149. See discussion supra Part II(C) (explaining the OBRA legislation
specifics).
150. See Greenough, supra note 25, at 398-99 (stating that the profession’s
code of ethics may be an acceptable way to establish the duty owed). For a
further discussion of the ethics standards applicable to pharmacists,
abrogating the learned intermediary doctrine, see discussion infra Part IV(B).
151. See Nail v. Publix Super Markets, Inc., 72 So.3d 608, 614 (Ala. 2011)
(determining that sufficient evidence through expert testimony established
that a duty to consult patients was an accepted custom).
152. Happel, 766 N.E.2d at 1127; Leesley, 518 N.E.2d at 763.
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clearly show that the profession itself should accept liability, the
learned intermediary doctrine should not shield pharmacists.
While there are multiple pharmacist codes of ethics or oaths
that exist, they are very similar.153 Pharmacists take these oaths
or undertake these codes to abide by the goals of the profession.
Because the profession creates these standards, it is logical that
these standards are an accurate gauge of how the pharmacy
profession determined that pharmacists should conduct
themselves.154 Although some of these standards seem vague,
courts should use these standards to impose liability regardless of
any protection under the learned intermediary doctrine.155 The
pharmacist standards are relevant here by looking at both the
purpose and the language of these standards.
Each of the pharmacist standards clearly has a purpose of
creating a responsibility to the patient, emphasizing the
“covenantal relationship”156 with him. Mainly, pharmacists are to
153. See AphA-ASP/AACP COD, supra note 7, at 101-02 (reproducing
multiple oaths and codes that pharmacists follow, making it easy to see the
similarities among them). Each code speaks of obligations to patients and the
goals and values of the profession. Id. Of the eight codes in the Code of Ethics
for Pharmacists, three are geared specifically toward patients, while the
remaining five are either geared toward other pharmacy professionals or
society at large. Id. at 102. Also, the Pledge of Professionalism mentions a
relationship to the patient in three of the five pledges. Id.
154. See Dale J. Atkinson, NABP Legal Briefs: Doody to Warn, NAT’L ASS’N
OF BOARDS OF PHARMACY (Dec. 10, 2010), http://www.nabp.net/news/nabplegal-briefs-doody-to-warn/ (stating that the pharmacy profession and patients’
trust is undermined when courts determine that pharmacists do not have a
duty to warn, contrary to professional standards). Specifically, Atkinson
attacks the Illinois decision in DiGiovanni, 940 N.E.2d 73, because the court
determined, without looking at the professional standards within the
pharmacy field, that there was no duty imposed on pharmacists. Id.; see also
LAURA A. CARPENTER & KENNETH R. BAKER, PHARMACISTS’ DUTY TO WARN:
SUGGESTING A BALANCE BETWEEN NO DUTY AND UNDOABLE DUTY 1, 16-17
(2007),
available
at
http://ebookbrowse.com/pharmacists-duty-to-warnsuggesting-a-balance-between-no-duty-and-an-undoable-duty-doc-d142904135
(stating that pharmacy professional standards are a tool to measure what is
expected of licensed pharmacists and that not holding pharmacists liable for
duties that the profession requires is a disservice to the pharmacy profession).
155. See AphA-ASP/AACP COD, supra note 7, at 101-02 (duplicating the
Oath of a Pharmacist, Pledge of Professionalism, and the Code of Ethics for
Pharmacists). For example, in the Oath of a Pharmacist, it states that a
pharmacist will “assure optimal drug therapy outcomes for the patients I
serve.” Id. at 101. It is open to debate to determine what “optimal” means.
Another example is from the Pledge of Professionalism, which states that the
pharmacist will “facilitate the covenantal relationship required of the
pharmaceutical caregiver.” Id. at 102. Also, in the Code of Ethics for
Pharmacists, it states that a pharmacist “respects the covenantal relationship
between the patient and pharmacist.” Id. What exactly is included in the
“covenantal relationship” needs further exploration.
156. See id. (showing that the covenantal relationship language is in both
the Pledge of Professionalism and the Code of Ethics for Pharmacists).
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uphold this covenantal relationship by competently serving their
patients to ensure that the “optimal therapeutic outcomes are
attained.”157
Further, the profession recognizes that knowledge of the
science of pharmacy is not the only responsibility of the profession;
equally as important is maintaining high ethics while treating
patients.158 This includes striving for “optimal patient care.”159 It
makes sense that to ensure “optimal patient care,” the drugs being
dispensed must not interact with one another.
Moreover, the language in the Code of Ethics for Pharmacists
displays the intent of the profession to take on responsibilities,
regardless of the protection of the learned intermediary
doctrine.160 Two phrases in particular are applicable to drug
interactions.
First, that “[a] pharmacist promotes the good of every patient
. . . .”161 This statement fits with the proposed requirement that a
pharmacist must warn the patient of drug interactions. The
possible consequences of not informing a patient of a potential
drug interaction could be deadly.162 Warning a patient of a drug
interaction and possibly avoiding the interaction would absolutely
“promote the good of [that] patient.”163 Opposite this, not
informing the patient, could have disastrous consequences and
does not serve the best interest of the patient.
Second, “[a] pharmacist respects the autonomy and dignity of
each patient.”164 This second phrase entails that the patient is
allowed to make his own decisions, furthering the need to warn of
drug interactions. When a patient is not notified of potential drug
interactions, he does not make a conscious choice. The patient, if
given a choice, may risk taking the medication, notify the doctor to
get a replacement medication that does not create an interaction,
or not take the medication at all. In effect, by not informing the
patient of the possible drug interaction, the pharmacist is making
this decision for the patient: the pharmacist is making the decision
that the patient should take the drug and risk an interaction. This
is not the best way to serve the patient and it certainly does not
157. Id. at 101.
158. Id.
159. Id. at 102.
160. Code of Ethics, supra note 6.
161. Id.
162. See Coll. of Am. Pathologists & Am. Assoc. of Clinical Chemistry,
Toxicology
Information
(July
17,
2009),
http://www.cap.org/apps/cap.portal?_nfpb=true&_pageLabel=home
(follow
“Reference Resources and Publications” link; then follow “Disease Diagnosis
and Prevention” link; then follow “Toxicology Information” link) (stating that
mixing prescription drugs can have severe consequences, even fatal ones).
163. Code of Ethics, supra note 6.
164. Id.
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appear to comport with the Code of Ethics for Pharmacists.
Pharmacists already voluntarily follow these standards of
conduct, ethics, and oaths,165 and they were created after the
inception of the learned intermediary doctrine.166 Pharmacists
should understand that not following their own profession’s codes
could have consequences on their patients and result in liability.167
It is reasonable, then, to require pharmacists to abide by these
codes or suffer the consequences in court.
The pharmacy profession has made it clear what standards
they intend to uphold.168 The courts must now recognize that
under both the purpose and the language of these professional
standards there is a duty to warn of drug interactions that should
not be abridged by the learned intermediary doctrine.
V. CONCLUSION
Through the years, pharmacists have embraced additional
roles and responsibilities.169 Regardless of the fact that some of
these duties were mandated with the imposition of OBRA and
subsequent state legislation,170 the pharmacy profession has
embraced its new role in health care. As such, pharmacists must
now accept the legal liability that comes with their redefined
health care role.
By imposing on pharmacists a duty to warn of drug
interactions, not only are patients further protected from harm,
but also the goals of the pharmacy profession are upheld. The
learned intermediary doctrine should no longer shield pharmacists
from liability; doing so only undermines the very oaths the
pharmacist has sworn to uphold. A pharmacist’s duty to warn of
drug interactions will more adequately protect the patient and
should be embraced by all courts.

165. See AphA-ASP/AACP COD, supra note 7, at 101-02 (stating at the end
of both the Oath of a Pharmacist and the Pledge of Professionalism that the
person taking the oath/pledge does so voluntarily).
166. See Sterling, 370 F.2d at 85 (articulating the learned intermediary
doctrine for the first time in 1966). The Code of Ethics and Oath of the
Pharmacist, were not adopted until 1994. AphA-ASP/AACP COD, supra note
7, at 101-02. Looking at the timeline, the learned intermediary doctrine was
created first.
167. See CARPENTER & BAKER, supra note 154, at 1 (explaining that
pharmacists are dissatisfied and believe it undermines the profession when a
court decides not to impose a higher duty on pharmacists by determining that
they are practically mere order fillers).
168. See AphA-ASP/AACP COD, supra note 7, at 101-02 (duplicating the
standards of ethics and oaths that the pharmacy profession has adopted).
169. Cacciatore, supra note 16, at 104.
170. See supra notes 55-57 and accompanying text (explaining further
OBRA and subsequent state regulation).
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